"Baseline Anemia Ups Physician-Guided DAPT Discontinuation Rates After PCI" - Yael L. Maxwell
Patients with baseline anemia undergoing PCI are more likely to discontinue dual antiplatelet therapy under physician guidance within one year—a strategy deemed safe—than their nonanemic counterparts, according to new data from the PARIS registry. Dr. Mehran and colleagues looked at more than 4,000 PCI patients from the PARIS registry with baseline hemoglobin data available, of whom 18 percent were anemic “It is important to kind of think about the anemic patients not just in terms of bleeding, but also in terms of ischemic events when you disrupt or discontinue therapy,” said author of the study Roxana Mehran, MD, director of interventional cardiovascular research and clinical trials at the Zena and Michael A. Weiner Cardiovascular Institute at the Icahn School of Medicine at Mount Sinai.
— Roxana Mehran, MD, Director, Interventional Cardiovascular Research and Clinical Trials, The Zena and Michael A. Weiner Cardiovascular Institute, Professor, Medicine, Cardiology, Population Health Science and Policy, Icahn School of Medicine at Mount Sinai
